Previous study showed that PARP1 hyperactivation leads to therapeutic resistance, and the therapeutic potential of PARP inhibition in combination with cisplatin has shown profound anti-cancer effect in cervical cancer [18]. This evidence concerns the gene PARP1 and cervical carcinoma.